Developer docs
API playgroundTry for free, no card

Search company profiles

QuantHealth

Full company profile

uuid0000236

Namestring
QuantHealth
Legal namestring
QuantHealth Ltd.
Websiteurl
quanthealth.ai
Company typeenum
Private
Founded yearint
2020
Descriptiontext

QuantHealth Ltd. is an Israel-based AI clinical trial simulation company founded in 2020 by Orr Inbar (CEO) and Arnon Horev (CSO/Operations), headquartered in Tel Aviv at the Azrieli Triangle Tower with a US commercial office in Worcester, Massachusetts. The company operates an enterprise platform that simulates clinical trial outcomes at single-patient resolution rather than cohort averages, by combining a proprietary biomedical knowledge graph (5M+ datapoints from 30+ curated sources mapping the biological cascade from therapeutic entity to target, pathway, cell, anatomy, and disease) with a real-world multimodal dataset spanning 350 million lives and over 10,000 data points per patient. On top of this data layer sits the Large Real-World Drug Model (LRDM v1.0), described as the industry's first pharmaco-clinical foundation model for life sciences, capable of processing 100M+ patients and billions of therapeutic datapoints in a single simulation. The platform is organized into Clinical Development (protocol optimization, indication selection, TPP, probability of technical success, market forecasting, enrollment prediction), Business Development (search & evaluation, asset diligence & valuation), and Portfolio Management (asset prioritization, gaps and opportunities) modules, with a newer Predictive Competitive Positioning capability bridging clinical and commercial strategy. Prospectively validated endpoint prediction accuracy is reported at 85% on primary endpoints (IMVOKE010, TROPION-Breast, ELOQUENT-1), with up to 90% prediction accuracy across the 600+ simulated clinical trials in nearly 30 therapeutic areas.

QuantHealth sells primarily to top-50 global pharmaceutical and biotechnology sponsors under quote-based, multi-year enterprise contracts accessed through "Book a Demo" CTAs; pricing is not publicly disclosed. Revenue mechanics combine platform subscriptions with strategic co-development engagements functioning as a land-and-expand motion. The company has reported 8x sales growth in 2025 and has cited customer outcomes including $31.4M in savings delivered to a top-10 pharma, $256M from salvaging a phase 3 head-and-neck cancer trial, and $141M from accelerated MASH trial timelines. The company is privately held under QuantHealth Ltd. (Israeli jurisdiction) and has raised approximately $17M+ to date: a $15M Series A in August 2023 led by Bertelsmann Investments and Pitango VC, a ~$2M strategic investment from Accenture Ventures via Project Spotlight in January 2024, and an undisclosed strategic investment from Sanofi Ventures in October 2025. Certifications include ISO 27001, SOC 2 Type 2, SOC 3, and GDPR/UK GDPR compliance with Standard Contractual Clauses for international transfers.

Short descriptiontext

QuantHealth Ltd. is an Israel-based AI company providing an enterprise clinical trial simulation platform powered by its proprietary LRDM v1.0 pharmaco-clinical foundation model and 350M-life real-world database, serving top-50 global pharmaceutical and biotechnology sponsors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersTel Aviv, Israel
HQ citystring
Tel Aviv
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial simulation, AI drug development, patient digital twins, protocol optimization, pharmaceutical AI platform
Product category
AI Clinical Trial Simulation Software
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Enterprise clinical trial simulation platform subscriptions
TypeSubscription Recurring
Description

Primary revenue stream from licensed access to the QuantHealth clinical trial simulation platform sold to pharmaceutical and biotechnology sponsors under enterprise agreements. Sales growth was 8x in 2025 and the platform has been deployed across 600+ simulated trials and ~30 therapeutic areas. Pricing is not publicly disclosed; engagement model is quote-based and accessed via 'Book a Demo' CTAs.

quanthealth.ai
2Strategic / co-development engagements with life sciences organizations
TypeProfessional Services
Description

Revenue driven by new and expanding engagements with life sciences organizations, including deep protocol-design and portfolio-prioritization engagements (e.g., the top-10 pharma deployment that delivered $31.4M in savings). Functions as a land-and-expand motion on top of platform subscriptions.

morningstar.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations
Pricing details1 tier
1Enterprise engagement — quote-based, not publicly disclosed
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is not publicly disclosed; customers engage via 'Book a Demo' / 'Contact Us' and contracts are negotiated. Terms & Conditions reference paid Services and limit liability to amounts paid in the preceding 12 months, indicating contract-based recurring engagements rather than listed tier pricing.

quanthealth.ai
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

QuantHealth sells an AI-powered clinical trial simulation platform that simulates how individual patients will respond to any investigational or approved therapy at patient-level resolution. Built on a 350M-life real-world database, a proprietary biomedical knowledge graph, and the LRDM v1.0 foundation model, the platform supports protocol design and optimization, indication selection, probability of technical success, enrollment and market forecasting, business development asset diligence, and portfolio prioritization for pharmaceutical and biotechnology sponsors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 8x sales growth in 2025 across life sciences organizations
+6 more records
Product overview1 text field

QuantHealth offers a single unified AI-powered clinical trial simulation platform, augmented by a proprietary pharmaco-clinical foundation model (Large Real-World Drug Model / LRDM v1.0). The platform is organized into three primary solution areas — Clinical Development (protocol design & optimization, indication selection, TPP, PTS, market forecasting, enrollment prediction), Business Development (search & evaluation, comparative deep dive, asset diligence & valuation, out-licensing & disposition), and Portfolio Management (asset prioritization, asset synergy & overlap, gaps & opportunities) — with a newer Predictive Competitive Positioning capability bridging clinical and commercial strategy. The underlying LRDM foundation model, together with an integrated biomedical, clinical, and epidemiological data framework covering 350M lives and 100K+ drug entities, powers patient-level simulation of treatment response at 85–90% accuracy across nearly 30 therapeutic areas.

Product and service1 record
1QuantHealth Platform
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Unlearn.AI
TypeDirect peer
Description

AI-driven clinical trial simulation platform focused on generating prognostic control arms and forecasting patient outcomes; directly comparable to QuantHealth's patient-level digital-twin approach for protocol design.

TypeDirect peer
Description

AI for clinical research and drug development, applying machine learning to real-world patient data to optimize trial design and predict treatment response; comparable AI-for-clinical-trials positioning.

TypeDirect peer
Description

Real-world evidence and AI-driven clinical trial solutions for pharma and biotech; competes in the same enterprise pharma AI/clinical-development category.

4Tempus AI
TypeBroad incumbent
Description

Large real-world data and AI platform serving oncology and broader clinical development across pharma; overlaps with QuantHealth's real-world data-driven simulation but at much broader scale.

TypeBroad incumbent
Description

Enterprise clinical trial technology platform used by most large pharma sponsors; a broad incumbent competing for protocol design and simulation budget alongside QuantHealth.

TypeEmerging player
Description

AI-driven drug discovery and clinical development company; shares the AI-for-pharma-clinical-decisions positioning but is more drug-discovery-focused than trial-simulation-focused.

TypeEmerging player
Description

AI-driven drug discovery platform combining high-throughput biology with ML; comparable AI-for-life-sciences positioning with broader drug-discovery scope.

TypeEmerging player
Description

AI foundation-model-driven drug discovery and clinical development; adjacent through shared pharma AI and foundation model narratives.

TypeEmerging player
Description

AI-augmented drug discovery platform serving pharma R&D; comparable AI-for-pharma enterprise SaaS model, though focused upstream on discovery.

TypeBroad incumbent
Description

Largest CRO and clinical development technology vendor with deep data assets; competes for the same clinical trial simulation and protocol optimization wallet.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

QuantHealth

AI Clinical Trial Simulation Softwarequanthealth.ai

QuantHealth Ltd. is an Israel-based AI company providing an enterprise clinical trial simulation platform powered by its proprietary LRDM v1.0 pharmaco-clinical foundation model and 350M-life real-world database, serving top-50 global pharmaceutical and biotechnology sponsors.

What QuantHealth does

QuantHealth Ltd. is an Israel-based AI clinical trial simulation company founded in 2020 by Orr Inbar (CEO) and Arnon Horev (CSO/Operations), headquartered in Tel Aviv at the Azrieli Triangle Tower with a US commercial office in Worcester, Massachusetts. The company operates an enterprise platform that simulates clinical trial outcomes at single-patient resolution rather than cohort averages, by combining a proprietary biomedical knowledge graph (5M+ datapoints from 30+ curated sources mapping the biological cascade from therapeutic entity to target, pathway, cell, anatomy, and disease) with a real-world multimodal dataset spanning 350 million lives and over 10,000 data points per patient. On top of this data layer sits the Large Real-World Drug Model (LRDM v1.0), described as the industry's first pharmaco-clinical foundation model for life sciences, capable of processing 100M+ patients and billions of therapeutic datapoints in a single simulation. The platform is organized into Clinical Development (protocol optimization, indication selection, TPP, probability of technical success, market forecasting, enrollment prediction), Business Development (search & evaluation, asset diligence & valuation), and Portfolio Management (asset prioritization, gaps and opportunities) modules, with a newer Predictive Competitive Positioning capability bridging clinical and commercial strategy. Prospectively validated endpoint prediction accuracy is reported at 85% on primary endpoints (IMVOKE010, TROPION-Breast, ELOQUENT-1), with up to 90% prediction accuracy across the 600+ simulated clinical trials in nearly 30 therapeutic areas.

QuantHealth sells primarily to top-50 global pharmaceutical and biotechnology sponsors under quote-based, multi-year enterprise contracts accessed through "Book a Demo" CTAs; pricing is not publicly disclosed. Revenue mechanics combine platform subscriptions with strategic co-development engagements functioning as a land-and-expand motion. The company has reported 8x sales growth in 2025 and has cited customer outcomes including $31.4M in savings delivered to a top-10 pharma, $256M from salvaging a phase 3 head-and-neck cancer trial, and $141M from accelerated MASH trial timelines. The company is privately held under QuantHealth Ltd. (Israeli jurisdiction) and has raised approximately $17M+ to date: a $15M Series A in August 2023 led by Bertelsmann Investments and Pitango VC, a ~$2M strategic investment from Accenture Ventures via Project Spotlight in January 2024, and an undisclosed strategic investment from Sanofi Ventures in October 2025. Certifications include ISO 27001, SOC 2 Type 2, SOC 3, and GDPR/UK GDPR compliance with Standard Contractual Clauses for international transfers.

QuantHealth firmographics

Firmographics
Name
QuantHealth
Legal name
QuantHealth Ltd.
Website
https://quanthealth.ai
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
51–100 employees
Short description
QuantHealth Ltd. is an Israel-based AI company providing an enterprise clinical trial simulation platform powered by its proprietary LRDM v1.0 pharmaco-clinical foundation model and 350M-life real-world database, serving top-50 global pharmaceutical and biotechnology sponsors.
Ownership category
akta.pro rank

Where QuantHealth is headquartered

Location

Headquarters

HQ city
Tel Aviv
HQ country
Israel
HQ region
Middle East

Offices2 records

Markets served

QuantHealth business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations

Revenue model

  1. Enterprise clinical trial simulation platform subscriptions: Primary revenue stream from licensed access to the QuantHealth clinical trial simulation platform sold to pharmaceutical and biotechnology sponsors under enterprise agreements. Sales growth was 8x in 2025 and the platform has been deployed across 600+ simulated trials and ~30 therapeutic areas. Pricing is not publicly disclosed; engagement model is quote-based and accessed via 'Book a Demo' CTAs.
  2. Strategic / co-development engagements with life sciences organizations: Revenue driven by new and expanding engagements with life sciences organizations, including deep protocol-design and portfolio-prioritization engagements (e.g., the top-10 pharma deployment that delivered $31.4M in savings). Functions as a land-and-expand motion on top of platform subscriptions.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractEnterprise engagement — quote-based, not publicly disclosed

Go-to-market motion1 record

Marketing channels6 records

QuantHealth product offering

Product offering

Core offering

QuantHealth sells an AI-powered clinical trial simulation platform that simulates how individual patients will respond to any investigational or approved therapy at patient-level resolution. Built on a 350M-life real-world database, a proprietary biomedical knowledge graph, and the LRDM v1.0 foundation model, the platform supports protocol design and optimization, indication selection, probability of technical success, enrollment and market forecasting, business development asset diligence, and portfolio prioritization for pharmaceutical and biotechnology sponsors.

Product overview

QuantHealth offers a single unified AI-powered clinical trial simulation platform, augmented by a proprietary pharmaco-clinical foundation model (Large Real-World Drug Model / LRDM v1.0). The platform is organized into three primary solution areas — Clinical Development (protocol design & optimization, indication selection, TPP, PTS, market forecasting, enrollment prediction), Business Development (search & evaluation, comparative deep dive, asset diligence & valuation, out-licensing & disposition), and Portfolio Management (asset prioritization, asset synergy & overlap, gaps & opportunities) — with a newer Predictive Competitive Positioning capability bridging clinical and commercial strategy. The underlying LRDM foundation model, together with an integrated biomedical, clinical, and epidemiological data framework covering 350M lives and 100K+ drug entities, powers patient-level simulation of treatment response at 85–90% accuracy across nearly 30 therapeutic areas.

Differentiator

Problem solved

Functional benefit

Products and services

  • QuantHealth Platform

Quantifiable outcome

  • 8x sales growth in 2025 across life sciences organizations
  • +6 more outcomes

Companies that use QuantHealth

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

QuantHealth technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability9 records

Feature7 records

QuantHealth partnerships and signals

Strategic signal

Scale indicators11 records

Recent moves5 records

Expansion highlights6 records

QuantHealth competitors and assessment

Company assessment

Direct peers

  • Unlearn.AI: AI-driven clinical trial simulation platform focused on generating prognostic control arms and forecasting patient outcomes; directly comparable to QuantHealth's patient-level digital-twin approach for protocol design.
  • Owkin: AI for clinical research and drug development, applying machine learning to real-world patient data to optimize trial design and predict treatment response; comparable AI-for-clinical-trials positioning.
  • ConcertAI: Real-world evidence and AI-driven clinical trial solutions for pharma and biotech; competes in the same enterprise pharma AI/clinical-development category.

Broad incumbents

  • Tempus AI: Large real-world data and AI platform serving oncology and broader clinical development across pharma; overlaps with QuantHealth's real-world data-driven simulation but at much broader scale.
  • Medidata Solutions (Dassault Systèmes): Enterprise clinical trial technology platform used by most large pharma sponsors; a broad incumbent competing for protocol design and simulation budget alongside QuantHealth.
  • IQVIA: Largest CRO and clinical development technology vendor with deep data assets; competes for the same clinical trial simulation and protocol optimization wallet.

Emerging players

  • Exscientia: AI-driven drug discovery and clinical development company; shares the AI-for-pharma-clinical-decisions positioning but is more drug-discovery-focused than trial-simulation-focused.
  • Recursion: AI-driven drug discovery platform combining high-throughput biology with ML; comparable AI-for-life-sciences positioning with broader drug-discovery scope.
  • Insilico Medicine: AI foundation-model-driven drug discovery and clinical development; adjacent through shared pharma AI and foundation model narratives.
  • Cyclica: AI-augmented drug discovery platform serving pharma R&D; comparable AI-for-pharma enterprise SaaS model, though focused upstream on discovery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

QuantHealth social profiles

Digital presence

QuantHealth compliance and trust

Trust signal

Compliance4 records

QuantHealth financial estimates

Financial estimate

Revenue estimate

Valuation estimate

QuantHealth leadership team

Management profile

Number of profiles

Profiles15 records

QuantHealth funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

QuantHealth M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about QuantHealth

What does QuantHealth do?

QuantHealth sells an AI-powered clinical trial simulation platform that simulates how individual patients will respond to any investigational or approved therapy at patient-level resolution. Built on a 350M-life real-world database, a proprietary biomedical knowledge graph, and the LRDM v1.0 foundation model, the platform supports protocol design and optimization, indication selection, probability of technical success, enrollment and market forecasting, business development asset diligence, and portfolio prioritization for pharmaceutical and biotechnology sponsors.

Is QuantHealth a public or private company?

QuantHealth is a private company. It is classified as venture growth investor backed and is currently operating.

When was QuantHealth founded?

QuantHealth was founded in 2020. It employs 51 to 100 people.

Where is QuantHealth based?

QuantHealth is headquartered in Tel Aviv, Israel, in the Middle East region.

How does QuantHealth make money?

Two revenue lines are on record. Enterprise clinical trial simulation platform subscriptions are the primary driver. The others are strategic / co-development engagements with life sciences organizations.

Who are QuantHealth's main competitors?

Direct peers on record are Unlearn.AI, Owkin and ConcertAI. Broad incumbents are Tempus AI, Medidata Solutions (Dassault Systèmes) and IQVIA. Emerging players are Exscientia, Recursion, Insilico Medicine and Cyclica.

Does QuantHealth have an API?

No public API is recorded for QuantHealth.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogQuantHealth Marks a Landmark Quarter as Simulation-First Clinical Development Gains MomentumQuantHealth closed a $45 million Series B to fund R&D and go-to-market expansion. Its predictive competitive positioning solution was adopted by three leading life sciences organizations, and the company expanded into new therapeutic areas and partnerships with GC Cell and NovelWise.FinancialContent Business PageQuantHealth Marks a Landmark Quarter as Simulation-First Clinical Development Gains MomentumQuantHealth closed a $45 million Series B to fund R&D and go-to-market expansion. Its predictive competitive positioning solution was adopted by three leading life sciences organizations, and the company expanded into rare disease and neurological indications. The company also deepened partnerships, including with Databricks.Business Wire BlogGC Cell and QuantHealth Collaborate to Optimize Clinical Development of GCC2005GC Cell and QuantHealth announced a collaboration to apply AI-powered clinical trial simulation to GCC2005's Phase 2 multi-regional trial design. The partnership aims to refine patient selection and endpoints before enrollment, reducing uncertainty in the global development program.EIN PresswireNovelWise Announces QuantHealth Collaboration to Advance AI-Enabled Oncology DevelopmentNovelWise Pharmaceutical announced a collaboration with QuantHealth to integrate AI-driven clinical trial simulations into its oncology drug development. The partnership aims to support evidence-informed development decisions, complementing NovelWise's scientific expertise. AI-generated insights will be considered alongside scientific evidence and expert judgment.BusinesskoreaGC Cell Partners With QuantHealthGC Cell signed a joint research agreement with QuantHealth on Sep. 16 to use AI clinical simulation for designing its next clinical trial for GCC2005, a CD5 CAR-NK cell therapy. The companies plan to predict treatment responses and compare GCC2005 with competing treatments. GC Cell has completed Phase 1a enrollment and is preparing Phase 1b.Phirda临床试验AI CRO:融资7000万美金,Sanofi参与QuantHealth, an Israeli AI clinical trial simulation company, raised $45 million in a B round led by Qumra Capital, with Sanofi Ventures participating. The round brings cumulative funding to about $70 million. The company will use the funds to expand its platform and promote its 'simulation-first' clinical development approach.Digital Health NewsQuantHealth Secures $45 Mn to Expand AI Clinical Trial Simulations & Help Pharma Reduce Drug Development RiskIsrael-based clinical trial simulation startup QuantHealth has secured $45 million in Series B funding to expand its AI platform, strengthen predictive models, and increase disease coverage. The investment brings the company's total funding to $75 million and will support expansion from 30 to over 40 disease indications, with plans to extend the platform beyond trial design into commercial planning. QuantHealth's platform has already simulated over 600 clinical trials across 30 disease indications with up to 90% predictive accuracy, and 12 of the world's top 20 pharmaceutical companies are using its technology.The SaaS NewsQuantHealth Raises $45M Series BQuantHealth, a Tel Aviv-based developer of an AI-powered clinical trial simulation platform, has raised $45 million in Series B funding led by Qumra Capital, with participation from Pitango HealthTech, Sanofi Ventures, and other investors. This round brings the company's total funding to approximately $70 million and will be used to advance R&D, expand the team, and extend the platform into broader drug development processes. Founded in 2020 by CEO Orr Inbar, QuantHealth's platform simulates patient-level biology to predict clinical trial responses, aiming to reduce failure rates in drug development.MedCity NewsQuantHealth Snags $45M to Simulate Clinical Trials Before Patients Ever EnrollQuantHealth, an Israeli startup developing AI-powered clinical trial simulation platforms, has secured $45 million in Series B funding led by Qumra Capital, with participation from Sanofi Ventures, Pitango HealthTech, Artofin Venture Capital Fund, and Esplanade Ventures, bringing its total funding to $70 million since its 2020 founding. The platform simulates clinical trials virtually before patient enrollment, claiming up to 90% accuracy in predicting patient outcomes and aiming to address the pharmaceutical industry's 90% drug failure rate in clinical trials. The startup plans to use the proceeds to enhance its AI models, expand disease coverage, grow its team, and extend further into the drug development and commercialization journey.HIT ConsultantQuantHealth Secures $45M for AI Clinical Simulation PlatformQuantHealth, based in Tel Aviv, has secured $45 million in a Series B financing round led by Qumra Capital, with participation from several major investors including Sanofi Ventures. The funding will be used to enhance its AI clinical simulation platform, which aims to reduce the high failure rates in clinical trials by improving predictive accuracy in trial designs. With collaborations involving some of the world's largest pharmaceutical companies, QuantHealth is set to expand its offerings across more than 40 therapeutic indications.